Cresco Labs (CL) Q4 2025 earnings summary
Event summary combining transcript, slides, and related documents.
Q4 2025 earnings summary
5 Mar, 2026Executive summary
Achieved $162 million in Q4 2025 revenue and $656 million for the full year, with sequential margin improvement and strong operating cash flow, while maintaining No. 1 market share in multiple billion-dollar markets and operating 73 retail stores as of year-end.
Generated ~$73 million in operating cash flow for 2025, paid down ~$35 million in debt, and ended the year with ~$94 million in cash and equivalents.
Strengthened the balance sheet by refinancing debt, extending maturities to 2030, and exiting California to focus on higher-return markets.
Focused on organic growth in core markets, targeted expansion, and leveraging infrastructure for higher incremental returns.
Maintained leadership in branded market share in Illinois, Pennsylvania, and Massachusetts, and introduced new retail initiatives like the Sunnyside house brand LOUDER.
Financial highlights
Q4 2025 revenue was $162 million; full-year revenue reached $656 million.
Q4 adjusted gross profit was $84.4 million (52.2% margin); adjusted EBITDA was $40.4 million (25.0% margin); operating cash flow was $27 million.
Q4 net loss was ($88.9 million), primarily due to a $93.5 million impairment loss; FY 2025 net loss was $140 million, including $105 million in one-time, non-cash charges.
Ended the year with $94 million in cash and no near-term maturities.
Q4 free cash flow was $18 million; FY 2025 free cash flow was $38 million.
Outlook and guidance
Expect a high single-digit sequential revenue decline in Q1, mainly due to Michigan excise tax changes, California exit, seasonality, and ongoing price compression.
Gross margin expected to normalize from Q4's elevated levels due to seasonal mix shifts and competitive pricing.
SG&A to remain consistent with recent run rates; no repeat of prior period benefits like bad debt reserve reductions.
Operational improvements and disciplined capital allocation are expected to support performance growth and long-term expansion.
Management expects to capitalize on industry consolidation and potential federal reform, focusing on organic expansion and selective acquisitions.
Latest events from Cresco Labs
- All resolutions, including director elections and incentive plan changes, were approved.CL
EGM 20243 Feb 2026 - Q2 saw margin and cash flow gains, with growth expected as adult-use markets expand.CL
Q2 20242 Feb 2026 - All resolutions passed, directors elected, and shareholders invited to Q&A after formal business.CL
EGM 202519 Jan 2026 - Q3 2024 saw record cash flow, margin gains, and top market share amid strategic growth moves.CL
Q3 202415 Jan 2026 - Margin and cash flow gains drive growth and expansion despite revenue decline and tax charges.CL
Q4 202425 Dec 2025 - Vertically integrated U.S. cannabis operator launches multi-security shelf offering amid regulatory risks.CL
Registration Filing29 Nov 2025 - Q1 2025 delivered $166M revenue, strong cash flow, and market leadership despite margin pressure.CL
Q1 202525 Nov 2025 - Q2 2025 revenue hit $164M, 25% EBITDA margin, and debt refinancing supports future growth.CL
Q2 202523 Nov 2025 - Q3 2025 revenue hit $165M, with strong market share, improved cash flow, and debt refinancing.CL
Q3 202513 Nov 2025